{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:15:07Z","timestamp":1788290107351,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01577-w","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:31:10Z","timestamp":1788287470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Zolbetuximab: Next-Generation Targeting Strategies for CLDN18.2"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"1577_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"1577_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"1577_CR3","unstructured":"US Food and Drug Administration. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. Published October 18. 2024. Accessed July 18, 2026."},{"key":"1577_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41568-026-00913-3","volume":"26","author":"A Saviano","year":"2026","unstructured":"Saviano A, Toso A, Klempner SJ, Baumert TF. Claudin proteins as emerging therapeutic targets for solid tumours. Nat Rev Cancer. 2026;26:364\u201383. https:\/\/doi.org\/10.1038\/s41568-026-00913-3.","journal-title":"Nat Rev Cancer"},{"key":"1577_CR5","doi-asserted-by":"publisher","first-page":"10263","DOI":"10.1038\/s41598-026-39540-1","volume":"16","author":"B Zheng","year":"2026","unstructured":"Zheng B, Fu M, Lou F, et al. Claudin18.2 promote gastric cancer proliferation by activating MCM2\/5. Sci Rep. 2026;16:10263. https:\/\/doi.org\/10.1038\/s41598-026-39540-1.","journal-title":"Sci Rep"},{"key":"1577_CR6","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu MH, Kim HD, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep. 2024;14:17648. https:\/\/doi.org\/10.1038\/s41598-024-68411-w.","journal-title":"Sci Rep"},{"key":"1577_CR7","doi-asserted-by":"publisher","first-page":"e012683","DOI":"10.1136\/jitc-2025-012683","volume":"13","author":"SH Lim","year":"2025","unstructured":"Lim SH, et al. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J Immunother Cancer. 2025;13:e012683. https:\/\/doi.org\/10.1136\/jitc-2025-012683.","journal-title":"J Immunother Cancer"},{"key":"1577_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41416-025-02981-y","volume":"132","author":"C Tsutsumi","year":"2025","unstructured":"Tsutsumi C, et al. Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment. Br J Cancer. 2025;132:793\u2013804. https:\/\/doi.org\/10.1038\/s41416-025-02981-y.","journal-title":"Br J Cancer"},{"key":"1577_CR9","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41591-026-04306-9","volume":"32","author":"K Shitara","year":"2026","unstructured":"Shitara K, Shoji H, Fazio N, et al. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026;32:2182\u201390. https:\/\/doi.org\/10.1038\/s41591-026-04306-9.","journal-title":"Nat Med"},{"key":"1577_CR10","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang J, Sun Y, et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31:3028\u201336. https:\/\/doi.org\/10.1038\/s41591-025-03783-8.","journal-title":"Nat Med"},{"key":"1577_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Liu FR, Wei XL, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in advanced gastric\/gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(24)00636-3.","journal-title":"Lancet Oncol"},{"key":"1577_CR12","unstructured":"ClinicalTrials.gov. AZD0901 compared with investigator\u2019s choice of therapy in second-line or later CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma. NCT06346392. Accessed July 18, 2026."},{"key":"1577_CR13","doi-asserted-by":"publisher","first-page":"115808","DOI":"10.1016\/j.ejca.2025.115808","volume":"230","author":"C Bai","year":"2025","unstructured":"Bai C, Zheng Y, Sun M, et al. Tecotabart vedotin in Claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: a Bayesian phase 1\/2 clinical trial. Eur J Cancer. 2025;230:115808. https:\/\/doi.org\/10.1016\/j.ejca.2025.115808.","journal-title":"Eur J Cancer"},{"key":"1577_CR14","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","volume":"31","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Wu HX, Luo SX, et al. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nat Med. 2025;31:3037\u201346. https:\/\/doi.org\/10.1038\/s41591-025-03781-w.","journal-title":"Nat Med"},{"key":"1577_CR15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405:2049\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00860-8.","journal-title":"Lancet"},{"key":"1577_CR16","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334. https:\/\/doi.org\/10.1038\/s41591-024-03037-z.","journal-title":"Nat Med"},{"key":"1577_CR17","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-24-4280","volume":"31","author":"G Ku","year":"2025","unstructured":"Ku G, Shen L, Dayyani F, et al. A first-in-human study of givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-positive advanced or metastatic solid tumors. Clin Cancer Res. 2025;31:4944\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4280.","journal-title":"Clin Cancer Res"},{"key":"1577_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12916-025-04597-8","volume":"24","author":"X Li","year":"2026","unstructured":"Li X, Dai R, Xu Q, et al. Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2 x CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. BMC Med. 2026;24:91. https:\/\/doi.org\/10.1186\/s12916-025-04597-8.","journal-title":"BMC Med"},{"key":"1577_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/acs.analchem.0c04055","volume":"93","author":"L Fan","year":"2021","unstructured":"Fan L, Chong X, Zhao M, et al. Ultrasensitive gastric cancer circulating tumor cellular CLDN18.2 RNA detection based on a molecular beacon. Anal Chem. 2021;93:665\u201370. https:\/\/doi.org\/10.1021\/acs.analchem.0c04055.","journal-title":"Anal Chem"},{"key":"1577_CR20","unstructured":"ClinicalTrials.gov. A study of IBI343 versus investigator\u2019s choice in previously treated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma (G-HOPE-001). NCT06238843. Accessed July 18, 2026."},{"key":"1577_CR21","unstructured":"ClinicalTrials.gov. A phase 1\/1b study of ASP2138 in participants with metastatic or unresectable gastric, gastroesophageal junction, or pancreatic cancer. NCT05365581. Accessed July 18, 2026."},{"key":"1577_CR22","unstructured":"ClinicalTrials.gov. Givastomig in combination with nivolumab and chemotherapy in CLDN18.2-positive metastatic gastroesophageal cancer. NCT04900818. Accessed July 18, 2026."}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01577-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:31:11Z","timestamp":1788287471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01577-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01577-w","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"204"}}